• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Lipofen (fenofibrate) Capsules, 50 mg and 150 mg

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

January 2013

Summary View

5 WARNINGS AND PRECAUTIONS

5.1 Coronary Heart Disease Morbidity and Mortality
  • results from the ACCORD Lipid trial
5.2 Skeletal Muscle
  • cases of myopathy, including rhabdomyolysis, have been reported in patients taking fenofibrates co-administered with colchicine
5.11 Paradoxical Decreases in HDL Cholesterol Levels
  • paradoxical decreases in HDL in patients taking fenofibrates

6 ADVERSE REACTIONS

6.2 Post-marketing Experience
  • paradoxical decreases in HDL in patients taking fenofibrates

7 DRUG INTERACTIONS

7.4 Colchicine
  • cases of myopathy, including rhabdomyolysis, have been reported in patients taking fenofibrates co-administered with colchicine